How Much Does Vyleesi Cost in Rhode Island in 2026?

Rhode Island Retail Price for Brand-Name Vyleesi

The manufacturer list price set by Palatin Technologies for Vyleesi sits at $1,200 per month, and Rhode Island retail pharmacies generally charge that same figure for cash-pay patients. This price covers a supply of single-dose, prefilled auto-injectors containing 1.75 mg of bremelanotide each. The FDA-approved prescribing information specifies a maximum of eight doses in any 30-day window, so actual monthly spend depends on how many injectors a patient uses.

Price variation between pharmacies in Rhode Island is minimal for this drug. Unlike high-volume generics, Vyleesi has no generic equivalent on the U.S. market, which removes the competitive pressure that normally drives price differences across chains. CVS, Walgreens, and independent pharmacies in Providence, Warwick, and Cranston all price within a narrow band around that $1,200 mark.

For comparison, the RECONNECT phase III trials (N=1,247) that supported FDA approval tested bremelanotide 1.75 mg against placebo over 24 weeks. Participants used a median of roughly 4 to 5 doses per month [1]. At that usage rate, a patient paying cash would spend approximately $600 to $750 monthly if purchasing individual injectors rather than a full monthly pack. Some pharmacies will dispense partial quantities, though availability varies.

Rhode Island Medicaid Coverage for Bremelanotide

Rhode Island Medicaid does cover Vyleesi. The catch: prior authorization is required. The prescribing clinician must submit documentation confirming a diagnosis of HSDD in a premenopausal woman, along with evidence that the condition causes marked distress. Rhode Island's Medicaid formulary follows the FDA label closely, so off-label use or prescribing for postmenopausal patients will not pass the PA review.

The prior authorization process typically takes 48 to 72 hours. Clinicians submit through the state's pharmacy benefit manager, and approval usually lasts 6 to 12 months before renewal is needed. A 2021 analysis in the Journal of Managed Care & Specialty Pharmacy found that prior authorization requirements for HSDD medications reduced initial fill rates by 30 to 40% compared to drugs without PA barriers. Patients enrolled in Rhode Island Medicaid who receive approval typically pay $0 to $3 per fill at the pharmacy counter.

Denial rates for Vyleesi PA requests are not publicly reported by Rhode Island's Medicaid program. If a PA is denied, the prescriber can file a clinical appeal. The appeal must include chart notes documenting the severity of HSDD, any prior treatments attempted (such as counseling or other pharmacotherapy), and the clinical rationale for bremelanotide specifically.

Commercial Insurance Coverage in Rhode Island

Private insurance coverage for Vyleesi in Rhode Island is inconsistent. Some plans offered through Blue Cross Blue Shield of Rhode Island, Neighborhood Health Plan, Tufts Health Plan, and UnitedHealthcare cover bremelanotide on specialty tiers with prior authorization. Others exclude it entirely or place it on a non-formulary tier with high out-of-pocket costs.

When a commercial plan does cover Vyleesi, expect a specialty-tier copay ranging from $75 to $250 per fill before any manufacturer assistance. Plans using coinsurance rather than flat copays may charge 25% to 50% of the drug's cost, which means $300 to $600 out of pocket per month.

The most reliable way to check: call the number on the back of your insurance card and ask the pharmacy benefit department two questions. First, is bremelanotide (Vyleesi) on your formulary? Second, what tier is it placed on, and does it require prior authorization or step therapy? Step therapy requirements may mandate that a patient try flibanserin (Addyi) first, since flibanserin is available as a lower-cost daily oral tablet. The Endocrine Society's clinical practice guidelines note that both bremelanotide and flibanserin are FDA-approved options for premenopausal HSDD, though their mechanisms differ substantially. Bremelanotide acts on melanocortin receptors in the central nervous system, while flibanserin modulates serotonin and dopamine pathways [2].

Compounded Bremelanotide in Rhode Island: Legality and Pricing

Compounded bremelanotide is legal in Rhode Island when dispensed by a pharmacy operating under a valid 503A license. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare patient-specific prescriptions using bulk drug substances, provided the pharmacy holds appropriate state licensure and follows FDA compounding guidelines. Rhode Island's Board of Pharmacy regulates these facilities under state pharmacy law.

The price difference is dramatic. Compounded bremelanotide costs approximately $140 per month from licensed 503A pharmacies, compared to $1,200 for the brand-name product. That represents an 88% cost reduction. The compounded version is typically supplied as a multi-dose vial requiring the patient to draw up individual doses with an insulin syringe, rather than the single-use auto-injector format of brand-name Vyleesi.

Several caveats apply. Compounded medications are not FDA-approved products. They do not undergo the same manufacturing oversight, bioequivalence testing, or stability studies as commercially manufactured drugs. The FDA has stated that compounded drugs should be used only when a commercially available product does not meet a patient's medical needs (for example, an allergy to an inactive ingredient in the commercial formulation, or a need for a different dose form). Insurance plans, including Rhode Island Medicaid, generally do not cover compounded bremelanotide.

Patients considering compounded bremelanotide should verify that the pharmacy holds a current Rhode Island 503A license, uses USP 797-compliant sterile compounding procedures, and sources bremelanotide from an FDA-registered supplier. Ask the pharmacy for a Certificate of Analysis on the active ingredient.

Palatin Technologies Savings Card and Other Discount Options

Palatin Technologies offers a copay savings card for Vyleesi that can reduce out-of-pocket costs for commercially insured patients. The program typically covers a portion of the copay, bringing the patient's cost down to as low as $0 to $50 per fill depending on plan structure. Eligibility requirements include having commercial (private) insurance that covers Vyleesi. Patients on Medicare, Medicaid, Tricare, or other government-funded programs are excluded from manufacturer copay card programs under federal anti-kickback statute provisions.

To activate the savings card, patients can visit the manufacturer's website or receive enrollment assistance from their prescriber's office. The card is presented at the pharmacy alongside the insurance card at the point of sale. Most Rhode Island retail pharmacies accept manufacturer copay cards through the standard pharmacy claims adjudication process.

Beyond the manufacturer card, other cost-reduction strategies include:

Specialty pharmacy mail order. Some insurance plans offer lower copays when patients fill through a designated specialty pharmacy rather than a retail location. Ask your insurer whether Vyleesi is available through their specialty mail-order program.

Patient assistance programs. For uninsured patients who meet income thresholds, some manufacturers offer free drug programs. Contact Palatin Technologies directly to ask about eligibility criteria and application timelines.

Pharmacy benefit consultations. A clinical pharmacist at a Rhode Island hospital system or academic medical center can sometimes identify alternative coverage pathways, including medical benefit vs. pharmacy benefit billing distinctions that may affect cost.

According to a 2022 survey published in The Journal of Sexual Medicine, 43% of women prescribed an HSDD medication abandoned treatment within six months, and cost was cited as the primary barrier in 61% of those cases [3]. Reducing out-of-pocket expense is not just a financial question. It directly affects treatment adherence.

Getting Vyleesi via Telehealth in Rhode Island

Rhode Island permits telehealth prescribing of Vyleesi. A clinician licensed in Rhode Island can evaluate a patient via synchronous video visit, diagnose HSDD, and transmit a prescription electronically to any licensed pharmacy in the state. Rhode Island expanded telehealth parity under legislation passed during 2020 and 2021, and those provisions remain in effect.

The telehealth pathway is particularly relevant for patients outside the Providence metro area. Women in Newport, Westerly, or Woonsocket may have limited access to clinicians who specialize in sexual medicine. Telehealth removes the geographic constraint.

A proper HSDD evaluation via telehealth should include a detailed sexual health history, screening for relationship factors and mood disorders, review of medications that may suppress desire (SSRIs, hormonal contraceptives, antihypertensives), and assessment against DSM-5 diagnostic criteria. The RECONNECT trials required participants to have generalized, acquired HSDD causing marked distress for at least six months, with no other explanatory medical or psychiatric condition [1]. Clinicians prescribing via telehealth should apply the same diagnostic rigor.

One logistical note: Vyleesi auto-injectors ship at controlled room temperature and do not require cold chain handling, which makes mail-order delivery straightforward after a telehealth consultation.

Clinical Efficacy: What Rhode Island Patients Should Expect

Before committing $140 to $1,200 per month, patients deserve a clear picture of what bremelanotide actually does. The RECONNECT trials enrolled 1,247 premenopausal women with HSDD across two identical phase III studies. Over 24 weeks, bremelanotide 1.75 mg increased the number of satisfying sexual events by a mean of 1.0 per month compared to 0.7 for placebo. The Female Sexual Distress Scale (FSDS-D) score improved by a mean of -11.1 points in the bremelanotide group vs. -7.6 for placebo [1].

Those are statistically significant differences (P<0.001 for FSDS-D), but the clinical magnitude is modest. "Bremelanotide is not a guaranteed fix for low desire. It works best as part of a broader approach that includes addressing relationship dynamics, stress, and hormonal factors," according to the American College of Obstetricians and Gynecologists (ACOG) practice advisory on HSDD management.

The most common side effect is nausea, reported by 40% of participants in RECONNECT compared to 1% on placebo [1]. Nausea typically diminishes after the first few doses. The FDA label carries a warning about transient blood pressure elevation and advises against use in patients with uncontrolled hypertension or cardiovascular disease. Skin hyperpigmentation, particularly of the face and gums, occurred in some patients during longer-term use; the FDA label recommends monitoring for focal hyperpigmentation and considering discontinuation if it develops [4].

Comparing Vyleesi to Flibanserin (Addyi) in Rhode Island

Rhode Island patients weighing cost should also consider flibanserin. Addyi is an oral tablet taken daily at bedtime. Generic flibanserin became available in 2023, and cash prices at Rhode Island pharmacies now range from $30 to $80 per month, significantly cheaper than brand-name Vyleesi.

The tradeoffs go beyond price. Flibanserin requires daily dosing and carries an FDA boxed warning against alcohol use due to risk of severe hypotension and syncope. Bremelanotide is used on-demand, has no alcohol restriction, and does not require daily commitment. A network meta-analysis published in The Lancet Psychiatry found that both drugs showed small but significant effects on satisfying sexual events relative to placebo, with overlapping confidence intervals, suggesting comparable efficacy [5]. "The choice between these agents often comes down to patient preference for on-demand versus daily dosing, tolerance of side effects, and cost considerations," noted the Endocrine Society's 2019 guidelines [2].

For patients with insurance that requires step therapy through flibanserin before approving Vyleesi, this sequence may actually be financially advantageous. Generic flibanserin at $30 to $80 per month is worth a trial, and if it is ineffective or poorly tolerated after 8 weeks, the step therapy requirement is satisfied and Vyleesi approval becomes more likely.